{
  "docId": "019de075-1362-766d-ac60-1333cab868aa",
  "docSlug": "7fe2865adefd4e627357f5c080658aba",
  "documentTitle": "Alkermes | Investor Presentation Deck | 56 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 56,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a four-column layout to summarize key business pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1362-766d-ac60-1333cab868aa/7",
  "deckHref": "/decks/019de075-1362-766d-ac60-1333cab868aa",
  "deckJsonHref": "/decks/019de075-1362-766d-ac60-1333cab868aa.json",
  "deckAnchorHref": "/decks/019de075-1362-766d-ac60-1333cab868aa#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.28,
        "y": 0.35
      },
      "kind": "list",
      "text": "ADVANCED PIPELINE OF NOVEL DEVELOPMENT CANDIDATES: Neuroscience (ALKS 2680, Discovery Programs) and Oncology (Nemvaleukin Alfa, IL-12 & IL-18).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a102a9e-52cf-4fd2-be1a-7db9d6ed268a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "list",
      "text": "COMMITMENT TO STRONG CORPORATE GOVERNANCE: 7 new independent directors, 5 longer-serving directors retired, Financial Operating Committee established, declassification of the Board initiated.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "343b8134-eb85-43e8-80d7-e9bae565b826",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "TARGETED FOOTPRINT AND CAPABILITIES: Sophisticated commercial infrastructure, disciplined R&D, advanced medicinal chemistry, manufacturing in U.S. and Ireland, oncology separation planned.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a891c7ac-dfbc-4abd-aab7-125dcfb12758",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "list",
      "text": "ATTRACTIVE COMMERCIAL PORTFOLIO IN ADDICTION AND PSYCHIATRY: Brought 3 differentiated proprietary products to market: VIVITROL®, ARISTADA®, LYBALVI®. Proprietary revenues increased by 75% from FY2019 to FY2023E. Long-dated patent lives.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf6ff7a4-c504-4da6-99e6-830056b59d38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1 Represents increase in net sales from FY2019 to FY2023E. 2 Reflects midpoint of financial expectations provided on June 6, 2023. * Separation of oncology business expected to be completed H2 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7a6cf64-03b1-40da-b437-6df7180c6752",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Alkermes at a Glance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29852ca4-ac56-43fd-b862-b100555ebe31",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "68d8a1f2-d240-4f13-a19a-30fee9c81b21",
      "evidence": "The slide uses a list/bullet format to present information about the company's commercial portfolio, corporate governance, and pipeline.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 4,
      "beatId": "11d99372-f0f0-424e-bb3a-bf91dc8ef04e",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Current Reality (Pain)",
      "beatSlug": "transformation-tale-current-reality-pain",
      "evidence": "Slides 4-7 highlight Alkermes' transformation and current state.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}